Robert (Bob) H. Underwood, PhD, helps clients achieve business objectives by drawing on his extensive experience establishing US and international intellectual property (IP) rights and identifying and evaluating third-party IP risks. He focuses his practice on the life sciences and chemical industries, including biologic and small-molecule pharmaceuticals and diagnostics, vaccines, medical devices, food science and nutritional supplements, agricultural technology, renewable and clean chemical technology, organic chemistry, polymers and catalysts.
Bob represents corporate companies of all sizes, from start-ups to mature multinationals, nonprofits and universities, as well as venture capital and private equity investors. He regularly assists clients with the following matters:
Patent portfolio development and management
Invalidity and freedom to operate opinions
Transactions and agreements that involve IP rights, including joint development agreements, sponsored research agreements, licenses and corporate transactions
Bob also assists clients with product planning matters, patent lifecycle management, and the acquisition and divestment of intellectual property assets. He has experience with contentious IP matters, including patent interferences and oppositions, and pre-litigation planning.
Bob has prior experience as visiting scientist at the Basel Institute for Immunology in Switzerland and as a research associate at Brigham and Women’s Hospital in Boston. He earned his doctoral degree in immunology and his bachelor’s degree in biology.
Serves as IP counsel to Novartis on several transactions, including the approximately $7 billion sale of its vaccines business to GlaxoSmithKline, the sale of its influenza vaccines business to CSL and in evaluating business development opportunities
Serves as counsel to pharmaceutical companies for early stage evaluation of potential in-licensing and M&A opportunities
Served as IP transaction counsel, pro bono, to the ALS association
Served as IP counsel to Synageva and provided IP portfolio strategy, prosecution and IP counseling services in connection with the company’s pipeline products; Synageva was acquired by Alexion for approximately $8.5 billion
Serves as IP counsel to a family office and provides transaction and patent prosecution services in connection with their life science research and development initiatives
Serves as IP counsel to many start-up companies, including Domantis (acquired by GSK for $500 million), Applied Therapeutics, Spyryx, Pulmatrix, Protein Dynamic Solutions and Incredible Foods
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.